New hope for kids with rare cancers: brigatinib trial opens
NCT ID NCT04925609
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called brigatinib in children and young adults (ages 1 to 25) with certain ALK-positive cancers, including anaplastic large cell lymphoma and inflammatory myofibroblastic tumors. The goal is to find the best dose and see how safe and effective the drug is. About 65 participants will take brigatinib pills daily for up to 2 years.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institut Gustave Roussy
RECRUITINGParis, 94805, France
-
Princess Máxima Center for Pediatric Oncology
RECRUITINGUtrecht, Utrecht, 3584 CS, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shield nerves from Chemotherapy's side effects?
- Can a Tumor's DNA guide better cancer care for kids?
- Can a new PET tracer reveal a key cancer target?
- Can a smart drug home in on Hard-to-Treat cancers?
- Can a new tracer light up cancer growth?
- Can a Dual-Pronged antibody outsmart advanced cancers?